Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel total assets
Total assets on the balance sheet at the end of each period.
Vericel's total assets was $517.11M at Sep 30, 2026. For fiscal 2025 it was $487.97M, up 12.8% from the year before. Over ten years it grew 30.4% a year on average. The highest annual figure on record is $487.97M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $487.97M | +12.8% |
| FY2024 | Dec 31, 2024 | $432.72M | +22.4% |
| FY2023 | Dec 31, 2023 | $353.66M | +29.5% |
| FY2022 | Dec 31, 2022 | $273.00M | +12.0% |
| FY2021 | Dec 31, 2021 | $243.71M | +18.5% |
| FY2020 | Dec 31, 2020 | $205.61M | +34.2% |
| FY2019 | Dec 31, 2019 | $153.24M | +29.1% |
| FY2018 | Dec 31, 2018 | $118.69M | +117.5% |
| FY2017 | Dec 31, 2017 | $54.58M | +12.3% |
| FY2016 | Dec 31, 2016 | $48.60M | +41.6% |
| FY2015 | Dec 31, 2015 | $34.31M | -27.9% |
| FY2014 | Dec 31, 2014 | $47.58M | +416.3% |
| FY2013 | Dec 31, 2013 | $9.22M | -39.3% |
| FY2012 | Dec 31, 2012 | $15.18M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $517.11M | +14.1% |
| Q2 FY2026 | Jun 30, 2026 | $502.87M | +15.4% |
| Q1 FY2026 | Mar 31, 2026 | $485.63M | +14.4% |
| Q4 FY2025 | Dec 31, 2025 | $487.97M | +12.8% |
| Q3 FY2025 | Sep 30, 2025 | $453.27M | +16.1% |
| Q2 FY2025 | Jun 30, 2025 | $435.61M | +15.6% |
| Q1 FY2025 | Mar 31, 2025 | $424.59M | +19.0% |
| Q4 FY2024 | Dec 31, 2024 | $432.72M | +22.4% |
| Q3 FY2024 | Sep 30, 2024 | $390.41M | +22.7% |
| Q2 FY2024 | Jun 30, 2024 | $376.84M | +21.3% |
| Q1 FY2024 | Mar 31, 2024 | $356.66M | +34.5% |
| Q4 FY2023 | Dec 31, 2023 | $353.66M | +29.5% |
| Q3 FY2023 | Sep 30, 2023 | $318.13M | +28.3% |
| Q2 FY2023 | Jun 30, 2023 | $310.71M | +26.9% |
| Q1 FY2023 | Mar 31, 2023 | $265.10M | +10.3% |
| Q4 FY2022 | Dec 31, 2022 | $273.00M | +12.0% |
| Q3 FY2022 | Sep 30, 2022 | $248.02M | +10.7% |
| Q2 FY2022 | Jun 30, 2022 | $244.82M | +10.3% |
| Q1 FY2022 | Mar 31, 2022 | $240.29M | +13.6% |
| Q4 FY2021 | Dec 31, 2021 | $243.71M | +18.5% |
| Q3 FY2021 | Sep 30, 2021 | $224.14M | +42.3% |
| Q2 FY2021 | Jun 30, 2021 | $221.95M | +51.3% |
| Q1 FY2021 | Mar 31, 2021 | $211.46M | +40.7% |
| Q4 FY2020 | Dec 31, 2020 | $205.61M | +34.2% |
| Q3 FY2020 | Sep 30, 2020 | $157.50M | +14.5% |
| Q2 FY2020 | Jun 30, 2020 | $146.69M | +16.6% |
| Q1 FY2020 | Mar 31, 2020 | $150.27M | +6.4% |
| Q4 FY2019 | Dec 31, 2019 | $153.24M | +29.1% |
| Q3 FY2019 | Sep 30, 2019 | $137.53M | +10.5% |
| Q2 FY2019 | Jun 30, 2019 | $125.83M | +3.0% |
| Q1 FY2019 | Mar 31, 2019 | $141.23M | +169.5% |
| Q4 FY2018 | Dec 31, 2018 | $118.69M | +117.5% |
| Q3 FY2018 | Sep 30, 2018 | $124.46M | +209.0% |
| Q2 FY2018 | Jun 30, 2018 | $122.19M | +234.5% |
| Q1 FY2018 | Mar 31, 2018 | $52.41M | +29.1% |
| Q4 FY2017 | Dec 31, 2017 | $54.58M | +12.3% |
| Q3 FY2017 | Sep 30, 2017 | $40.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $36.53M | – |
| Q1 FY2017 | Mar 31, 2017 | $40.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $48.60M | – |
See a number that looks wrong?